Bisphosphonates for cancer patients: why, how, and when?

  title={Bisphosphonates for cancer patients: why, how, and when?},
  author={J. J. Body and Isabelle Mancini},
  journal={Supportive Care in Cancer},
Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, and it is well accepted that tumor cells in bone, especially breast cancer and myeloma cells, can stimulate osteoclast formation and activity leading to the release of growth factors or cytokines, which will further stimulate cancer cells' growth and their secretion of osteolytic factors. BPs are now the standard treatment for cancer hypercalcemia, for which a dose of 90 mg of pamidronate or 1500 mg of… CONTINUE READING